Media - EverGlade Consulting

EverGlade Consulting in the Media

Prepaire Appoints Everglade Consulting to Secure Non-Dilutive Federal Government Funding for Multiple Projects

Prepaire Labs, an AI-driven biotechnology company powering drug discovery, repurposing, designing, and development, today announced the appointment of Everglade Consulting, a national consulting firm assisting biotechnology companies to secure non-dilutive federal funding.

EverGlade Consulting Helps Land up to $1 Billion in BARDA Funding for Biotechnology Company

EverGlade Consulting has helped a leading biotechnology company land an award from the Biomedical Advanced Research and Development Authority (BARDA) with a potential $1 billion in federal funding.

EverGlade Consulting Launches DOE Loan and CHIPS Support Practices

EverGlade Consulting (“EverGlade”), a national consulting firm, with employees in locations across the country, has launched two new practices to support recent legislation. EverGlade has been on the forefront of U.S. Government (“USG”) efforts to broaden the nation’s domestic industrial base to accommodate the manufacturing of critical supplies and materials.

EverGlade Consulting opens Washington, DC office

The Charleston, SC-headquartered firm said the DC office was a “logical next location for a physical presence.” EverGlade has already cut the ribbon on the office and is planning to recruit for roles in regulatory affairs, quality assurance, program management, project management, and government contract administration and compliance.

EverGlade Consulting Continues Growth, Opens Washington, D.C. Office Location

EverGlade Consulting (“EverGlade”), a national consulting firm, with employees in locations across the country, has opened an office location in Washington, D.C. in the heart of Chinatown. EverGlade’s new office is located at 700 K Street N.W.

EverGlade Consulting Plays Key Role on Industrial Base Expansion (IBx) Project with $39 Million in Federal Funding Secured

CHARLESTON, S.C., Aug. 24, 2022 /PRNewswire/ — EverGlade Consulting (“EverGlade”), a national consulting firm, has successfully partnered with a global leader in mRNA materials used for research, diagnostics, and therapeutics, to successfully manage $39 million in federal funding.

EverGlade Consulting Plays Key Role on Industrial Base Expansion Project with $150 Million in Federal Funding Secured

CHARLESTON, S.C., Aug. 19, 2022 /PRNewswire/ — EverGlade Consulting (“EverGlade”), a national consulting firm, has successfully partnered with one of the world’s leading providers of drug delivery technologies to successfully secure and manage $150 million in federal funding. The project will contribute to the global expansion of pharmaceutical lipids in the United States.

EverGlade Consulting Formalizes Industrial Base Expansion (IBx) Practice

EverGlade Consulting (“EverGlade”) formally establishes a team within the company dedicated to supporting U.S. Government (USG) funded Industrial Base Expansion (IBx) programs. This new group will build upon the success EverGlade has experienced in this space over the last few years.

EverGlade Consulting Formalizes Charleston, SC Headquarters with New Office Location

CHARLESTON, S.C., April 1, 2022 /PRNewswire/ — EverGlade Consulting (“EverGlade”), has opened an office location in Charleston, South Carolina as part of its expansion into the Southeast, formalizing its headquarter’s location. The company plans to recruit for positions in regulatory affairs, quality assurance, program management, project management, and government contract administration and compliance […]

EverGlade Consulting Assists Detect, Inc. with Securing $22m in Federal Funding for the Development of a Next Generation Molecular Test for COVID-19 and Flu

WASHINGTON, March 7, 2022 /PRNewswire/ — EverGlade Consulting (“EverGlade”), a Washington, D.C. based consulting firm, has successfully aided Detect, Inc. (“Detect”) in securing a contract with BARDA for the advanced development of a next generation diagnostic device […] an over-the-counter home test that identifies and distinguishes between SARS-CoV-2 and influenza A and B nucleic acid using a single nasal swab.

Scroll to Top